These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 9625322)
21. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. Bai M; Yang Z; Qi X; Fan D; Han G J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108 [TBL] [Abstract][Full Text] [Related]
22. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats. Vogels BA; Karlsen OT; Mass MA; Boveé WM; Chamuleau RA J Hepatol; 1997 Jan; 26(1):174-82. PubMed ID: 9148009 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345 [TBL] [Abstract][Full Text] [Related]
24. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463 [TBL] [Abstract][Full Text] [Related]
25. [Hepatic encephalopathy. L-ornithine-L-aspartate stimulate detoxification capacity of the liver]. Ameri AA MMW Fortschr Med; 2010 Jun; 152(22):42-3. PubMed ID: 20590033 [No Abstract] [Full Text] [Related]
26. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Ndraha S; Hasan I; Simadibrata M Acta Med Indones; 2011 Jan; 43(1):18-22. PubMed ID: 21339541 [TBL] [Abstract][Full Text] [Related]
27. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. Jiang Q; Jiang XH; Zheng MH; Chen YP J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Acharya SK; Bhatia V; Sreenivas V; Khanal S; Panda SK Gastroenterology; 2009 Jun; 136(7):2159-68. PubMed ID: 19505424 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials. He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493 [TBL] [Abstract][Full Text] [Related]
30. [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]. Zhou ZW; Zhong XN; Zhou BY; Xiang JF; Wang RH; Yi J Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):385-8. PubMed ID: 24025143 [TBL] [Abstract][Full Text] [Related]
31. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Butterworth RF; McPhail MJW Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425 [TBL] [Abstract][Full Text] [Related]
32. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure. Pérez Hernández JL; Higuera de la Tijera F; Serralde-Zúñiga AE; Abdo Francis JM Ann Hepatol; 2011 Jun; 10 Suppl 2():S66-9. PubMed ID: 22228885 [TBL] [Abstract][Full Text] [Related]
33. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage. Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172 [TBL] [Abstract][Full Text] [Related]
34. Letter to the editor: l-ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Kovalic AJ; Lee TP; Da BL Hepatology; 2022 Nov; 76(5):E108-E109. PubMed ID: 35788964 [No Abstract] [Full Text] [Related]
35. Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction. Stadlbauer V; Tauss J; Portugaller HR; Stiegler P; Iberer F; Stauber RE Metab Brain Dis; 2007 Mar; 22(1):45-50. PubMed ID: 17165154 [TBL] [Abstract][Full Text] [Related]
36. Effects of L-carnitine in patients with hepatic encephalopathy. Malaguarnera M; Pistone G; Elvira R; Leotta C; Scarpello L; Liborio R World J Gastroenterol; 2005 Dec; 11(45):7197-202. PubMed ID: 16437672 [TBL] [Abstract][Full Text] [Related]
37. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Malaguarnera M; Greco F; Barone G; Gargante MP; Malaguarnera M; Toscano MA Dig Dis Sci; 2007 Nov; 52(11):3259-65. PubMed ID: 17393330 [TBL] [Abstract][Full Text] [Related]
38. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Jiang Q; Jiang G; Shi KQ; Cai H; Wang YX; Zheng MH Ann Hepatol; 2013; 12(5):803-9. PubMed ID: 24018499 [TBL] [Abstract][Full Text] [Related]
39. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine. Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025 [TBL] [Abstract][Full Text] [Related]
40. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Jain A; Sharma BC; Mahajan B; Srivastava S; Kumar A; Sachdeva S; Sonika U; Dalal A Hepatology; 2022 May; 75(5):1194-1203. PubMed ID: 34822189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]